MediWound (NASDAQ:MDWD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

MediWound Ltd. (NASDAQ:MDWD)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.82 and traded as low as $14.70. MediWound shares last traded at $14.82, with a volume of 64,553 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Finally, Oppenheimer reissued an “outperform” rating and set a $32.00 target price (down from $33.00) on shares of MediWound in a research report on Wednesday, May 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MediWound presently has a consensus rating of “Hold” and an average price target of $34.00.

MediWound Stock Performance

The company has a 50 day simple moving average of $15.41 and a two-hundred day simple moving average of $16.79. The firm has a market cap of $194.81 million, a PE ratio of -6.71 and a beta of 0.14.

MediWound (NASDAQ:MDWD) last released its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.During the same quarter in the previous year, the company posted ($0.07) earnings per share. As a group, research analysts predict that MediWound Ltd. will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other MediWound news, Director David Morton Fox acquired 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was acquired at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director owned 22,283 shares in the company, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MDWD. Rosalind Advisors Inc. raised its position in shares of MediWound by 84.0% in the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after acquiring an additional 341,993 shares during the period. Kotler Kevin purchased a new position in shares of MediWound in the 4th quarter valued at about $6,225,000. Millennium Management LLC raised its holdings in MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after purchasing an additional 136,884 shares during the period. UBS Group AG boosted its position in MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after purchasing an additional 68,756 shares in the last quarter. Finally, Menora Mivtachim Holdings LTD. boosted its position in MediWound by 348.8% during the third quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after purchasing an additional 61,039 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.